Flunarizine: Indications and Dosing
Flunarizine is indicated primarily for migraine prophylaxis (including vestibular migraine) at 10 mg daily, and should be considered as first-line preventive therapy for vestibular migraine based on the strongest available evidence.
Primary Indications
Episodic Migraine Prophylaxis
Flunarizine is effective for preventing episodic migraine attacks. A systematic review and meta-analysis demonstrates that flunarizine reduces headache frequency by approximately 0.4 attacks per 4 weeks compared to placebo, with effectiveness comparable to propranolol 1. The drug reduces attack frequency, duration, and severity, with one study showing an 82% reduction in a corrected migraine index 2.
Vestibular Migraine (Primary Indication)
Flunarizine should be the first-choice prophylactic agent for vestibular migraine based on randomized controlled trial evidence. At 10 mg daily, it significantly reduces both the frequency and severity of vertiginous episodes 3. A recent 2026 retrospective study of 402 patients showed an overall response rate of 81.6% (defined as ≥50% reduction in vertigo attacks), with mean vertigo frequency decreasing from 1.6 attacks/month to 0.2 attacks/month after 8 months 4. The drug is particularly effective in patients with long-standing or treatment-resistant vestibular disease 4.
Migraine-Associated Menière's Disease
Flunarizine is also effective for prophylaxis in migraine-associated Menière's disease (MAMD), with similar efficacy rates as seen in vestibular migraine 4.
Recommended Dosing
Standard dose: 10 mg orally once daily at bedtime
- Duration: Treatment should be continued for at least 2-4 months before assessing efficacy, as some patients require this extended period to demonstrate clear benefit 2
- Monitoring: Monthly follow-up during the first 2 months to assess symptom reduction in frequency, duration, and intensity of both headache and vertigo 5
- Pediatric use: Flunarizine appears effective in children, though specific dosing was not detailed in the evidence 1
Clinical Considerations
When to Use Flunarizine
- First-line for vestibular migraine with significant vestibular symptoms 3, 6
- Patients who have failed other preventive therapies (the 2026 study included 46% of patients who had previously failed at least one preventive agent) 4
- Episodic migraine requiring prophylaxis
- Consider earlier in patients with combined vestibular and headache symptoms
Expected Outcomes
- Vertigo: Significant reduction in frequency (p=0.001), duration (p=0.001), and intensity (p=0.009) 5
- Headache: Significant reduction in frequency (p=0.001) and duration (p=0.001) 5
- Response timeline: Effects may take 4 months to fully manifest in some patients 2
Common Adverse Effects
The most frequent side effects are:
- Somnolence (administer at bedtime to minimize impact)
- Weight gain
- Mild cognitive slowing
These effects are generally mild, reversible, and not significantly different from control groups 4, 1, 3. The antidopaminergic properties should be considered in clinical decision-making, particularly in patients with movement disorders 4.
Important Caveats
- Not FDA-approved in the United States: The FDA drug label evidence provided 7 refers to fluphenazine (an antipsychotic), not flunarizine—this appears to be a data error. Flunarizine is not currently FDA-approved in the U.S., though it is widely used internationally
- Vestibular testing: VEMP (vestibular evoked myogenic potential) changes do not correlate with clinical improvement, so these tests should not be used to monitor treatment response 5
- Headache vs. vertigo response: Flunarizine appears more effective for vestibular symptoms than headache symptoms in vestibular migraine 3
Comparison to Alternatives
- Cinnarizine (75 mg/day): Slightly less effective than flunarizine (77% vs 84% response rate, p=0.03) but still a reasonable alternative 4
- Propranolol: Comparable efficacy to flunarizine for migraine prophylaxis 1
- Recent U.S. guidelines 8, 9 do not include flunarizine in their recommendations, likely due to lack of FDA approval in the United States, instead recommending candesartan, telmisartan, CGRP antagonists, topiramate, and propranolol for migraine prophylaxis